Predictors of preeclampsia in women in the metformin in gestational diabetes (MiG) study

Barrett, Helen L., Dekker Nitert, Marloes, McIntyre, H. David, Hague, William M., Callaway, Leonie K. and Rowan, Janet (2014) Predictors of preeclampsia in women in the metformin in gestational diabetes (MiG) study. Journal of Diabetes and Metabolism, 5 7: 395.1-395.8. doi:10.4172/2155-6156.1000395

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ341987_OA.pdf Full text (open access) application/pdf 323.08KB 0

Author Barrett, Helen L.
Dekker Nitert, Marloes
McIntyre, H. David
Hague, William M.
Callaway, Leonie K.
Rowan, Janet
Title Predictors of preeclampsia in women in the metformin in gestational diabetes (MiG) study
Journal name Journal of Diabetes and Metabolism   Check publisher's open access policy
ISSN 2155-6156
Publication date 2014
Sub-type Article (original research)
DOI 10.4172/2155-6156.1000395
Open Access Status File (Publisher version)
Volume 5
Issue 7
Start page 395.1
End page 395.8
Total pages 8
Place of publication Los Angeles, CA, United States
Publisher Omics Publishing Group
Collection year 2015
Language eng
Formatted abstract
Background: Gestational Diabetes Mellitus (GDM), maternal obesity and pregnancy weight gain are associated with an increased risk of developing Preeclampsia (PE). The aim of this study was to examine the predictors of PE in women commencing pharmacotherapy for GDM in the Metformin in Gestational diabetes trial.

Descriptive and logistic regression analyses examined the relationship between maternal enrolment characteristics and later development of PE.

46 (6.3%) of 703 women developed PE. At enrolment ((30 (SD3.2) weeks gestation), women who later developed PE had higher HbA1c (6.14% (95%CI 5.84, 6.45) vs. 5.73% (95%CI 5.67, 5.78), P=0.003), fasting triglycerides (2.93 mmol/L (95%CI 2.57, 3.29) vs. 2.55mmol/L (95%CI 2.47, 2.62), P=0.03) and blood pressure. Their infants were born 9 days earlier (P<0.001) but were otherwise not different. In univariate analysis, the strongest positive predictors for PE were Polynesian ethnicity (OR 2.75 (95%CI 1.48, 5.09), P=0.001), personal or family history of PE (OR 2.65 (95%CI 1.36, 5.16), P=0.004), maternal HbA1c (OR 1.96 (95%CI 1.35, 2.89), P<0.001), triglycerides (OR 1.45 (95%CI 1.07,1.97), P=0.002), and weight gain from early pregnancy (OR 1.09 (95%CI 1.03,1.17), P=0.01). HDL-C was a negative predictor of PE (OR 0.29 (95%CI 0.09, 0.94), P=0.04). Following adjustment for Polynesian ethnicity and personal or family history of PE, and when further adjusted for HbA1c or early pregnancy BMI, these variables remained significant.

Treatment allocation and BMI were not associated with risk of PE. Personal or family history of PE, Polynesian ethnicity, degree of hyperglycemia, maternal triglycerides and weight gain prior to treatment signal increased risk of subsequent PE in women needing pharmacotherapy for GDM.
Keyword Gestational diabetes mellitus
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2015 Collection
School of Medicine Publications
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Thu, 16 Oct 2014, 15:00:26 EST by Marloes Dekker on behalf of Royal Brisbane Clinical School